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Abstract We previously developed (2-deoxyglucose)-(ABT-
263) combination therapy (2DG-ABT), which induces apopto-
sis by activating Bak in the mitochondria of highly glycolytic
cells with varied genetic backgrounds. However, the rates of
apoptosis induced by 2DG-ABT were lower in von Hippel-
Lindau (VHL)-deficient cancer cells. The re-expression of
VHL protein in these cells lowered IGF1R expression in a
manner independent of oxygen concentration. Lowering
IGF1R expression via small interfering RNA (siRNA) sensi-
tized the cells to 2DG-ABT, suggesting that IGF1R interfered
with the activation of apoptosis by the mitochondria. To deter-
mine which of the two pathways activated by IGF1R, the Ras-
ERK pathway or the PI3K-AKT pathway, was involved in the
impairment of mitochondria activation, the cells were treated
with a specific inhibitor of either PI3K or ERK, and 2DG-ABT
was added to activate the mitochondria. The apoptotic rates
resulting from 2DG-ABT treatment were higher in the cells
treated with the PI3K inhibitor, while the rates remained
approximately the same in the cells treated with the ERK
inhibitor. In 2DG-ABT-sensitive cells, a 4-h 2DG treatment
caused the dissociation of Mcl-1 from Bak, while ABT treat-
ment alone caused the dissociation of Bcl-xL fromBakwithout
substantially reducing Mcl-1 levels. In 2DG-ABT-resistant
cells, Mcl-1 dissociated from Bak only when AKT activity
was inhibited during the 4-h 2DG treatment. Thus, in VHL-
deficient cells, IGF1R activated AKT and stabilized the Bak-
Mcl-1 complex, thereby conferring cell resistance to apoptosis.
Keywords 2-deoxyglucose . ABT-263 . Apoptosis . PI3K .
Ras . ERK1/2 . AKT
Introduction
A single cancer cell that remains after surgery and/or chemo-
therapy can cause cancer recurrence [1]. Therefore, cancer
chemotherapy aims to eliminate all cancer cells. Given the
heterogeneity of cancer cells in a tumor, it is difficult to elim-
inate all cancer cells using a single agent that targets a partic-
ular gene product [2]. To develop a therapy capable of specif-
ically inducing apoptosis in cancer cells across varied genetic
backgrounds, we targeted cells with elevated glucose metab-
olism. In the body, such cells are present in inflamed tissues,
muscle cells under heavy exertion, cancer cells, and brain cells
and are precisely the cells identified by FDG-PET scans. To
target these cells, we previously developed the combination
therapy 2-deoxyglucose-ABT-263 (2DG-ABT) [3]. When
2DG is transported across the plasma membrane through the
glucose transporter, it is converted into 2DG-6-P by hexoki-
nase in the cytosol and becomes trapped in the cell. Because
2DG-6-P is a poor substrate for glucose-6-phosphatase, it ac-
cumulates in the cytosol, competitively inhibiting hexokinase
activity. As early as in 1954, 2DGwas tested in mouse models
of cancer [4]. However, at the pharmacological dose of 40mg/
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kg, 2DG only delays tumor growth. Thus, more recently, 2DG
has been evaluated in combination with other chemotherapeu-
tics [2]. When 2DG-6-P accumulates in the cell, it causes the
dissociation of the anti-apoptotic protein Mcl-1 from the mi-
tochondria, usually within 2–4 h, thus sensitizing cells to
mitochondria-dependent apoptosis. The precise molecular
mechanism of how 2DG induces the dissociation of Mcl-1
from Bak is not known [2].
ABT-263 (ABT) is a potent, orally bioavailable Bcl-2-
family inhibitor [5]. ABT binds specifically and with high
affinity to the Bcl-2 family of proteins, including Bcl-2, Bcl-
xL, and Bcl-w, but not Mcl-1, and releases these proteins from
the mitochondria [6]. ABT has limited use when used as a
single agent in cancer therapy; however, when used with other
chemotherapeutics, it can enhance their efficacies against he-
matologic tumors [7]. Recent evidence has suggested that un-
like 2DG, ABT can target quiescent cells. Additionally, ABT
has been observed to target and clear senescent hematopoietic
cells in progeria mouse models, rejuvenating their aged hema-
topoietic system [8].
When cells are exposed to both 2DG and ABT, the pro-
apoptotic Bak and Bax proteins are freed from all their inhib-
itory associations withMcl-1 and the rest of the Bcl-2 family of
proteins and become activated, releasing cytochrome c from
the mitochondria. The release of cytochrome c triggers the
formation of the apoptosome in the cytosol. The formation of
the apoptosome, often called the death executioner, and the
release of cytochrome c are often called the points of no return.
Thus, unlike other initiators of apoptosis, 2DG-ABT induces
apoptosis very quickly, circumventing the many steps that are
usually required and leading to the point of no return within a
few hours. As a single agent, neither 2DG nor ABT is very
effective [2]. However, when cells take up both agents, the two
agents synergize and induce apoptosis. Because ABT cannot
cross the blood-brain barrier, it accumulates in tissues outside
the brain. Thus, the 2DG-ABT combination therapy induces
apoptosis in cancer cells outside the brain [2]. The 2DG-ABT
combination has been shown to efficiently induce apoptosis in
p53-compromised, PTEN-deleted, highly chemo-resistant hu-
man prostate cancer cells xenografted into mice [3].
When 2DG is injected into the body, it accumulates in the
bladder within 4 h, and less than 50 % of the drug is found in
circulation. To mimic the environment of cancer cells in the
body, we used the following protocol for in vitro experiments:
10 mM 2DGwas added to culture medium containing 25 mM
glucose, and ABT-263 was added 2 h later; the cells were
washed 4 h after 2DG addition, after which, they were incu-
bated in fresh medium. We previously showed that when
2 mM 2DG is present in medium containing 5 mM glucose,
it synergizes with ABT [3]. However, because our cells grew
substantially faster in high-glucosemedium, we used a 10mM
2DG/25 mM glucose combination. Using this protocol, when
2DG-ABT was tested on various cancer cells in vitro, it
induced apoptosis in all types of cancer cells across varied
genetic backgrounds. However, its efficiency varied among
cell lines. For example, as a single agent, 2DG-ABT induced
apoptosis in over 94% ofMCF-7 breast cancer cells and PPC-
1 prostate cancer cells [3]. However, using an identical proto-
col, the apoptotic rates were well below 50 % in many renal
cancer cell lines. Accordingly, we investigated the reason un-
derlying resistance in renal cancer cell lines.
Results
The rates of apoptosis induced by 2DG-ABTwere lower
in VHL-deficient cancer cells under both normoxic
and hypoxic conditions
To improve the efficacy of 2DG-ABT combination therapy,
we investigated the cause of cancer cell resistance to 2DG-
ABT treatment. We found that the renal carcinoma cell line
RCC4 was moderately resistant to 2DG-ABT. In vitro, ABT
induced apoptosis in less than 20 % of these cells, even at a
10 μM concentration. However, when ABT was combined
with 2DG, the combination induced apoptosis in 25 % of
RCC4 cells at 1 μM ABT and in 55 % of cells at 10 μM
ABT (Sup Fig. 1). Given that 2DG combined with 1 μM
ABT has been shown to induce apoptosis in over 94 % of
PPC-1 prostate and MCF7 breast cancer cells [3], there must
be a resistance mechanism present in RCC4 cells. Because
RCC4 is deficient in the von Hippel-Lindau (VHL) tumor
suppressor gene, which is part of the oxygen sensory/
response pathway, hypoxia-inducible factor 1 (HIF1a) is con-
stitutively activated in RCC4. Thus, we tested whether the
HIF1a activation would cause RCC4 cell resistance to 2DG-
ABT. To test this hypothesis, in addition to the renal cell
carcinoma cell line RCC4, we used another renal cancer cell
line, UOK121, in which VHL is epigenetically silenced, along
with the RCC4 + VHL and UOK121 + VHL cell lines, which
were stably transfected with functional VHL. We also treated
UOK121 with 5-aza-2′-deoxycytidine (5-Aza-dCyd) for
10 days to demethylate its genomic DNA and restore VHL
expression [9]. All cells were assayed under normoxic (21 %
oxygen) and hypoxic (1 % oxygen) conditions, and the results
are shown in Fig. 1. The presence of VHL in RCC4 and
UOK121 cells restored sensitivity to 2DG-ABT induced apo-
ptosis (Fig. 1b: unpaired t tests; p = 0.054 for normoxic RCC4
cells, p = 0.051 for hypoxic RCC4 cells, p = 0.0020 for
normoxic UOK121 cells, and p = 0.0015 for hypoxic
UOK121 cells). Furthermore, UOK121 cells that were treated
with 5-Aza-dCyd to induce VHL expression were also sensi-
tized to 2DG-ABT (compare the bars representing UOK121
with the bars representing UOK121 + 5Aza in Fig. 1a).
Interestingly, whether the experiment was performed under
normoxic or hypoxic conditions had little effect on the
13296 Tumor Biol. (2016) 37:13295–13306
outcome (Fig. 1a: p values for unpaired t test varied from
0.3511 to 0.9513). Furthermore, HIF1a expression did not
influence the sensitivity of the cells to apoptosis. For example,
the sensitivities of RCC4 + VHL cells under hypoxia, and thus
Fig. 1 The rates of apoptosis induced by 2DG-ABTwere lower in VHL-
deficient cancer cells under both normoxic and hypoxic conditions. a The
renal cancer cell lines, RCC4, RCC4 +VHL, UOK121, UOL121 + VHL,
and UOK121 were treated with 5-Aza-dC (UOK121 + 5-Aza-dC) to
restore VHL expression. Subsequently, the cells were tested for sensitiv-
ity to 2DG-ABT combination therapy. First, the cells were treated with
10 mM 2DG and, 2 h later, with 10 mMABT. At 4 h from the start of the
combination treatment, the cells were washed and re-incubated in fresh
media. Cells were assayed under either normoxic (21 % oxygen) or hyp-
oxic (1 % oxygen) conditions and analyzed for propidium iodide incor-
poration by FACS. Graphs of the FACS data are shown. Inserted Panel.
Western blots of UOK121 cells treated with or without 5-Aza-dCyd. b
For ease of comparison, the rates of apoptosis of cells with or without
VHL were placed next to each other in this panel
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expressing HIF1a, and RCC4 + VHL cells under normoxia,
and thus not expressing HIF1a, to 2DG-ABT at 10 μM ABT-
263 were approximately the same (unpaired t test p = 0.9513
and HIF1a blots are in Fig. 2a). Thus, the presence of VHL
influences cellular sensitivity to apoptosis, but not necessarily
by activating the HIF1a transcription factor. We also noted that
in VHL-expressing UOK121 cells, there was noHIF1a expres-
sion, even under hypoxic conditions (Fig. 2a), most likely be-
cause the over-expressed VHL degrades HIF1a, even under
hypoxic conditions [9]. The results of more extensive testing
of the 2DG-ABTcombination using varying concentrations of
ABT from 0 to 10 μM are reported in Sup Fig. 1, and the
statistical analysis is shown in Sup Table 1. The results showed
that the addition of 2DG synergized with ABT, thereby in-
creasing the apoptotic rates in RCC4 cells with or without
VHL expression and in UOK121 cells with VHL expression,
as expected from previous studies [3, 10].
The absence of VHL stabilized IGF1R expression
independently of oxygen concentration and interfered
with mitochondria-dependent apoptosis
We searched the literature and databases for genes regulated
by VHL independent of oxygen concentration and found that
IGF1R is up-regulated in the absence of VHL, regardless of
the oxygen concentration. Yuen and colleagues found that
IGF1R protein levels are unaffected by hypoxia in clear cell
renal carcinoma with or without VHL, but exogenously intro-
duced VHL protein reduces both the promoter activity of
IGF1R and the stability of IGF1R mRNA independent of
oxygen concentration [11]. We independently verified that
IGF1R protein levels decreased when the VHL protein was
introduced into UOK121 and RCC4 cells (Fig. 2a). When we
depleted IGF1R from RCC4 using siRNA, we observed an
increased sensitivity of the cells to 2DG-ABT (Fig. 2c).
Furthermore, IGF1R depletion attenuated AKT phosphoryla-
tion (Fig. 2b). The application of 1 μM picropodophyllin, a
specific inhibitor of IGF1R, also attenuated AKT phosphory-
lation (Fig. 2b). Thus, in the medium, either IGF1 or insulin
activates IGF1R, and its signal is transduced to AKT.
Furthermore, the treatment of cells with 2DG up-regulates
multiple signal transduction pathways [12], as noted in
RCC4 cells (Fig. 2b). Zhou and colleagues suggested that
2DG up-regulates IGF1R by directly binding to its inhibitor,
IGFBP3 [12]. However, using purified recombinant proteins,
Pollak and colleagues showed that the binding between
IGF1R and IGFBP3 is not disrupted by 2DG [13]. Thus, the
molecular mechanism by which 2DG up-regulates multiple
signaling pathways remains unresolved. What is clear from
these data is that IGF1R is the major source of pro-survival
signals in cultured RCC4 cells. Onemodel explaining how the
absence of VHL confers cell resistance to 2DG-ABT is that in
the absence of VHL, IGF1R expression is up-regulated in
RCC4 and UOK121 cells, thus generating a pro-survival sig-
nal through PI3K-AKT and causing these cells to be resistant
to 2DG-ABT. In contrast, in RCC4 + VHL, UOK121 + VHL,
and UOK121 + 5Aza cells, VHL interferes with IGF1R ex-
pression, attenuating the PI3K-AKT pro-survival signal and
making these cells sensitive to 2DG-ABT. This possibility is
supported by our observation that there were significant dif-
ferences in the apoptotic rates of RCC4 cells, which express
IGF1R, RCC4 + VHL cells, which express moderate amounts
of IGF1R, and RCC4 cells depleted of IGF1R, which express
almost no IGF1R, after treatment with 10 mM 2DG and
10 μM ABT-263 (Figs. 1 and 2).
IGF1R activated both the Ras-ERK and PI3K-AKT
pathways, but only the latter pathway interfered
with mitochondria-dependent apoptosis
IGF1R, like EGFR and many other receptor tyrosine kinases
(RTKs), activates both the Ras-ERK proliferation pathway
and the PI3K-AKT pro-survival pathway. Activated Ras gen-
erates ERK signals through its association with Raf. Activated
Ras also directly activates PI3K. Thus, there is cross-talk be-
tween these two pathways in the early stages of IGFR-induced
signal transduction. However, after these signals reach PI3K
and ERK, we can clearly distinguish between the activation of
these two pathways. We were thus able to determine which of
these two pathways interferes with the apoptotic activation of
mitochondria.
To address this question, we used PD98509, a specific
inhibitor for ERK1/2, and LY294002, a specific inhibitor for
PI3K, in UOK121 cells, because in these cells, both Ras-ERK
and PI3K-AKT activities are robust and easily observable.
Pre-treatment of UOK121 cells with either inhibitor did not
interfere with ligand-induced IGF1R activation, even in the
presence of 2DG. However, PD98509 clearly blocked the
activation of ERK without interfering with PI3K, whereas
LY294002 specifically inhibited PI3K activation without in-
terfering with ERK, clearly distinguishing the two pathways
(Fig. 3a).
To induce apoptosis in UOK121 cells, we first pre-treated
UOK121 cells with 10 mM 2DG for 2 h. Then, either the
PI3K inhibitor or the ERK inhibitor was added for 5 min, prior
to the addition of 2 μM ABT-263. Two hours later, the cells
were washed and incubated in fresh medium overnight, until
the cell viability assay was performed. In PD98509-treated
cells, cell growth was arrested, but 2DG-ABT had little effect
on survival (Fig. 3b). In stark contrast, LY294002-treated cells
grew well, with approximately the same growth rate as un-
treated cells. However, with the additional treatment of 2DG-
ABT for only 4 h, most of the cells underwent apoptosis,
leaving very few surviving cells (Fig. 3b).
From these results, it appeared likely that in VHL-deficient
cells, IGF1R expression is stabilized, thus generating PI3K-
13298 Tumor Biol. (2016) 37:13295–13306
AKT pro-survival signals and interfering with the apoptotic
activation of mitochondria. Accordingly, we investigated
whether AKT interferes with the apoptotic activation of mito-
chondria by stabilizing the Bak-Mcl-1 association. To reduce
AKT activity, we used both LY294002 and siRNA to lower
the expression levels of isoforms 1 and 2.
Inhibiting AKT sensitized cells to 2DG-induced
dissociation of mcl-1 from Bak
The PI3K inhibitor LY294002 did not alter the Bak-Mcl-1
association on its own (Fig. 4b), but in combination with
2DG, it significantly disrupted the Bak-Mcl-1 complex, al-
most completely dissociating Mcl-1 from Bak. These obser-
vations were made during the 4-h treatment period, in which
there were no substantial changes in the levels of AKT and
Mcl-1 (Fig. 4a). Thus, the kinase activity, and not the levels, of
AKT must affect the stability of the Bak-Mcl-1 complex. The
results from UOK121 cells are shown in Fig. 4. Similarly, in
RCC4 cells, when the kinase activity of AKT was attenuated
by blocking the signal transduction from PI3K to AKT, treat-
ment with 2DG was sufficient to dissociate Mcl-1 from Bak
[10]. Next, we tested whether lowering the protein levels of
AKT could destabilize the Bak-Mcl-1 complex.
Depleting AKT isoforms destabilized the Bak-mcl-1
complex and sensitized cells to 2DG-ABT-induced
apoptosis
Because AKT activates the transcription of Mcl-1, the
prolonged absence of AKT may cause a loss of Mcl-1 expres-
sion, in which case, testing whetherMcl-1 associates with Bak
would not be useful. We circumvented this problem by
inactivating AKT with a PI3K kinase inhibitor and testing
the Bak-Mcl-1 association within 2 h of AKT inhibition. At
this time point, we observed minimal changes in Mcl-1 pro-
tein levels (Fig. 4). Although three known AKT isoforms are
expressed in RCC4 [14], we depleted only two of them, iso-
forms 1 and 2, using siRNA in RCC4 cells. Our anti-AKT
antibody used in this experiment recognizes all three isoforms
a
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Fig. 2 The absence of VHL stabilized IGF1R expression independent of
oxygen concentrations and interfered with mitochondria-dependent apo-
ptosis. aWestern blots of RCC4, RCC4 + VHL, UOK121, and UOK121
+ VHL cells cultured under normoxic (N) or hypoxic (H) conditions and
probed with antibodies against IGF1R, Hif1a, VHL, and beta-tubulin. b
Western blots of either RCC4- or IGF1R-depleted RCC4
(RCC4ΔIGF1R) cells treated with 2DG, the IGF1R specific inhibitor,
picropodophyllin (PPP), both, or left untreated. The blots were probed
with antibodies against phosphor-tyrosine-IGF1R, phosphor-serine473-
AKT, pan-IGF1R, pan-AKT ,and β-tubulin. c FACS analysis of RCC4-
and IGF1R-depleted RCC4 cells treated with 0–3 mM ABT, with or
without 2DG. d Comparison of apoptotic rates using 10 mM 2DG and
1 mM ABT-263 in RCC4 (28+/−3 %), RCC4-VHL (46.206 %+/−3.91)
and RCC4 cells in which IGF1R had been depleted, designated RCC4
delIGF1R (77+/−2). The unpaired t test results were *1p = 0.0052,
*2p = 0.0024, and *3p = 0.0003. We noted that RCC4 delIGF1R was
even more sensitive than RCC4 + VHL, in which there is some IGF1R
expression
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of AKT, but because these isoforms are almost the same size,
it is difficult to distinguish them. Nevertheless, after we treated
cells with siRNA for 36 h, the overall expression levels of the
AKT proteins were reduced (see ΔAKT1/2 in Fig. 5a). We
also observed that the Mcl-1 proteins had altered mobility
(compared with the mobility of the Mcl-1 bands in Fig. 5b),
and the amounts of Mcl-1 were slightly reduced. To test
whether the altered mobility was caused by caspases, we de-
pleted AKT isoforms 1 and 2 in the presence of the pan-
caspase inhibitor z-VAD. However, Mcl-1 still showed slight-
ly increased mobility in SDS-PAGE gels (Sup Fig. 3). Thus, it
appears likely that the Mcl-1 phosphorylation that occurs in
the presence of AKT1/2 played a role in this mobility shift.
Furthermore, because activated PI3K-AKT is known to up-
regulate Mcl-1 [15], the reduced levels of Mcl-1 protein in
AKT1/2-depleted cells may simply have been due to the re-
duced transcription of Mcl-1. Despite the reduced Mcl-1
levels, Bak and Mcl-1 co-immunoprecipitated in ΔAKT1/2
cells (Fig. 5b). However, in ΔAKT1/2 cells, 2DG readily
dissociated Bak from Mcl-1 (Fig. 5b). When we quantified
the number of cells 16 h later, ΔAKT1/2 cell growth was
reduced compared with that of the untreated cells (Fig. 5a).
However, more importantly, 2DG-ABT was substantially
more effective in reducing the number of liveΔAKT1/2 cells
compared with untreated cells. Thus, the most likely mecha-
nism for the resistance of VHL-defective renal cancer cells to
2DG-ABT therapy is that in the absence of VHL, IGF1R
expression is stabilized, thus activating AKT. Subsequently,
the activated AKT interferes with the 2DG-induced Bak-Mcl-
1 complex disassembly.
Discussion
Following our publication on the 2DG-ABT combination
treatment in 2011, the same combination has been tested on
gastrointestinal stromal tumors (GIST) by Muhlenberg and
colleagues [16]. Because these tumors have highly elevated
glucose uptake, they are ideal candidates for 2DG-ABT com-
bination therapy. Muhlenberg and colleagues also reported
that the glucose-2DG combination, when used at an approxi-
mately 2:5 M ratio, works well to enhance ABT-induced ap-
optosis, thus corroborating our findings [3], as well as those of
others [4]. In their article, however, how the treatment with
2DG enhanced ABT-induced apoptosis was not clarified.
Initially, the authors focused on the effect of 2DG on the
tyrosine kinase KIT and found that 2DG treatment inhibits
KIT and KIT-dependent signaling, including PI3K-AKT, in
some GIST cells. For example, incubating GIST-T1 cells in
medium containing 2 mM 2DG and 6.8 mM glucose for 24 h
diminished the phosphorylation of GIST and AKT. However,
this finding was not consistent in GIST430 cells, in which a
24-h incubation with 2DG was sufficient to diminish KIT
phosphorylation in the first experiment (Fig. 2a) but not in
pY-IGF1R
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Unt IGF1   IGF1
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Fig. 3 IGF1R activated both the Ras-ERK and PI3K-AKT pathways, but
only the latter pathway interfered with mitochondria-dependent apopto-
sis. a Serum-starved UOK121 cells were stimulated with or without
20 ng/ml of IGF1 for 10 min in the presence or absence of either
50 μM PD98509 (ERK inhibitor) or 50 μM LY29402 (PI3K inhibitor).
Cells were harvested and analyzed by western blotting using anti-
phospho-IGF1R, anti-pS473-AKT, anti-P(T202/Y204)-ERK, and anti-
IGF1R, PI3K, AKT, and ERK antibodies, as indicated. b UOK121 cells
were first treated with or without 10 mM 2DG for 2 h, after which, either
PD98509, LY294002, or DMSO was added for 5 min, prior to the addi-
tion of either 2 μM ABT-263 or DMSO for another 2 h. Then, the cells
were washed, re-seeded in fresh media, and incubated overnight. The
experiment was performed in triplicate, and live cells were counted the
next day. The error bars indicate the standard deviation
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the second (Fig. 4b). Consequently, AKT phosphorylation
was diminished in the first experiment but was substantially
higher in the second experiment. It is interesting to note that
GIST-T1 cells are sensitive to the KIT kinase inhibitor ima-
tinib (IC50 = 42 nM) [17], whereas GIST430 cells are resis-
tant to imatinib [18]. From our perspective, these results sug-
gest that GIST430 cells might be resistant to the KIT inhibitor
because they can activate the pro-survival AKT pathway in
the absence of KIT activity. Unfortunately, these questions
were not pursued in that article. When the authors combined
2DG with ABT, the apoptotic rates in the combination-treated
cells were slightly higher than that in cells treated with 2DG or
ABT alone. However, whether 2DG and ABTwork synergis-
tically to induce apoptosis was not addressed.
Muhlenberg and colleagues also examined other factors in-
volved in apoptosis, such as Mcl-1, Bcl-2, Bcl-xL, and Bim.
However, the authors observed only minor changes in the ex-
pression of these factors in response 2DG and did not discuss
how 2DG may enhance ABT-induced apoptosis via these pro-
teins. Last, in most of their in vitro experiments, 2DGwas left in
the medium for 24–144 h. These conditions do not translate
well to animal experiments because injected 2DG does not stay
in the circulation for more than several hours. Thus, unless 2DG
is infused, cancer cells in animals are not likely to be exposed to
2DG for more than a few hours. Accordingly, 2DG treatment
effectively reduced the viabilities of cultured GIST cells in 6-
day cytotoxicity assays. However, when the authors treated
mice xenografted with GIST-T1 cells by feeding them 1 g/kg
of 2DG daily for 2 weeks, contrary to their expectation, the
2DG-treated tumors grew faster than untreated tumors. When
they isolated the tumors from the untreated and 2DG treated
mice, they found that 2DG treatment had no effect on KIT or
pS-AKT
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Fig. 4 Inhibiting AKT sensitized UOK121 cells to 2DG-induced disso-
ciation of Mcl-1 from Bak. Cells were treated with 10 mM 2DG, 50 μM
LY294002, both, or left untreated for 4 h. The cells were harvested, and
whole cell extracts were analyzed by western blotting (a). Some cells
were also resuspended in immunoprecipitation buffer (see Materials and
Methods section) and immunoprecipitated with anti-Bak antibody (b;
upper panel), anti-Bak antibody in the presence of 2 μM ABT-263 (b;
middle panel), or with anti-Mcl-1 antibody (b; lower panel). The immu-
noprecipitates were analyzed by western blotting. For a preliminary ex-
periment showing that ABT-263 could disrupt binding between Bak and
Bcl-xL in vitro, see Sup Fig. 2
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its phosphorylation. Subsequently, the authors terminated their
experiments without testing the 2DG-ABT combination in
tumor-bearing mice. Using pharmacological doses of 2DG
(40–100 mg/kg [2, 19]), 2DG-induced delays in tumor growth
(tumor growth curve shifts along the X-axis) have been reported
numerous times in all types of cancers with varied genetic back-
ground, including our own studies. Because GIST cells are
known to have elevated glucose uptake, it would be of interest
to know whether there in vivo resistance to 2DG is specific to
GIST-T1 cells or whether it applies to all GIST cells.
Thus, we believe that it is important to design in vitro pro-
tocols to simulate what cancer cells in animals might experi-
ence. For this reason, we used an in vitro protocol in which the
cells were washed within 4 h of 2DG application [3, 10].
However, even with these improvements, there will be differ-
ences in what cancer cells experience in vitro and in vivo.
Most cancer cells in a large tumor exist as a dense cluster of
cancer cells in highly hypoxic conditions [20]. These cancer
cells adapt to the hypoxic environment by activating hypoxia-
induced factors [21]. Consequently, somemembers of the Bcl-
2 family of proteins [22, 23] and the anti-apoptotic protein
IAP-2 [24] are up-regulated, causing cell resistance to apopto-
sis (reviewed in Wouters et al. [25]). Furthermore, VHL-
deficient cancer cells activate many of the same hypoxia-
induced factors, even in the presence of normal levels of ox-
ygen. Thus, before conducting the experiments in the present
study, we hypothesized that the activation of hypoxia-induced
factors causes VHL-deficient renal cancer cells to be resistant
to 2DG-ABT. Contrary to our expectations, we found the
following: (1) the rates of 2DG-ABT-induced apoptosis in
RCC4 cells, with or without functional VHL, were not influ-
enced by oxygen concentration; (2) the absence of VHL sta-
bilized IGF1R expression independently of oxygen concen-
tration; and (3) IGF1R-generated signals interfered with apo-
ptotic signals in the mitochondria. These findings clearly dem-
onstrated that hypoxia-activated VHL does not play a role in
the 2DG-ABT-induced apoptotic pathway. It has also been
reported that ABT induces apoptosis in hypoxic conditions
just as effectively as in normoxic conditions [26]. We believe
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Fig. 5 Partial depletion of AKT sensitizes RCC4 cells to 2DG-induced
dissociation of Mcl-1 from Bak, thereby sensitizing cells to 2DG-ABT
induced apoptosis. (a; left panel)AKT isoforms 1 and 2were depleted from
RCC4 with siRNA for 36 h, and the resulting cells are indicated as
ΔAKT1/2. These cells and untreated cells were analyzed by western blot-
ting. (a; right panel) These cells were assayed for 2DG-ABT-induced ap-
optosis, as in Fig. 3b. Live cells were counted, and the results are shown in
the graphs. (b; WCL) RCC4 and ΔAKT1/2 were also incubated with
10 mM 2DG for 4 h, and the whole cell lysates analyzed by western
blotting. (b; Mcl-1 IP and Bak IP panels). 2DG-treated and untreated cells
were also re-suspended in immunoprecipitation buffer and incubated with
anti-Mcl-1 or anti-Bak antibodies. The immunoprecipitates were analyzed
by western blotting
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concentration because, with the exception of Mcl-1, ABT
binds to all members of the Bcl-2 family of proteins with high
specificity and high affinity [5]. Hence, several fold differ-
ences in the levels of Bcl-2 family proteins do not influence
the outcome.
Thus, we sought to identify other underlying reasons for
the observed resistance and found that the IGF1R expression
was stabilized in the absence of VHL. When the IGF1R pro-
tein was depleted by siRNA, the cells became sensitized to
2DG-ABT. When we analyzed which signal transduction cas-
cades generated by IGF1R interfered with the 2DG-ABT-
induced apoptotic pathway, we found that PI3K-AKT had
profound effects on 2DG-ABT-induced apoptosis.
AKT regulates multiple proteins involved in cell growth
and survival, such as Cyclin D, GSK3B, Forkhead, mTOR,
and BAD [27], and it is likely that one of these pathways
activated by AKT may interfere with the 2DG-ABT-induced
apoptotic pathway. By inhibiting GSK3B, which can phos-
phorylate and destabilize Mcl-1, AKT may potentially play a
pro-survival role in 2DG-ABT induced apoptosis [28]. AKT
also up-regulates Mcl-1 by activating its transcription.
However, because 2DG-ABT induces apoptosis very quickly,
releasing cytochrome c without altering Mcl-1 protein levels,
these two pathways are not likely to be involved in the 2DG-
ABT-induced apoptotic pathway. Upon closer examination,
we found that a 4-h treatment of cells with the PI3K inhibitor
LY294002 sensitized the Bak-Mcl-1 association, while main-
taining the cellular protein levels of Mcl-1. Furthermore, at-
tenuating AKT activity by inhibiting IGF1R or PI3K or by
lowering AKT protein levels all lead to the destabilization of
the Bak-Mcl-1 association. Thus, we concluded that in VHL-
deficient cells, IGF1R activates AKT through PI3K, and AKT
stabilizes the Bak-Mcl-1 complex, thereby making these cells
resistant to mitochondria-dependent apoptosis. Accordingly,
we were able to induce apoptosis in RCC4 or UOK121 cells
(Fig. 6). First, we added 10 mM 2DG to the medium contain-
ing 25 mM glucose. Then, we lowered AKT activity by
blocking either IGF1R or PI3K activity. Within 4 h, Mcl-1
was displaced from Bak. When we added ABT-263, which
binds to all other Bcl-2 family members with high affinities,
Bcl-xL was displaced from Bak. When freed from all its in-
hibitory associations, Bak is spontaneously activated, forming
pores on the mitochondrial outer membranes, through which
cytochrome c is released into the cytosol. In the cytosol, cy-
tochrome c assembles apoptosomes, large protein complexes
with protease activities. The apoptosomes are often called the
death executioner because they cleave many proteins and are
involved in the last step of the mitochondria-dependent apo-
ptotic pathway.
One more issue remained to be addressed, namely, the mo-
lecular mechanism underlying the 2DG-induced dissociation
of Mcl-1 from Bak. To this end, we identified a protein that
binds to Mcl-1 when it is not associated with Bak. Currently,
we are attempting to determine whether this protein binds
competitively to Mcl-1, causing Bak-Mcl-1 dissociation, or
whether it merely binds to Mcl-1 in the absence of the Bak-
Mcl-1 association. We hope to report our new findings soon.
Applying the above concept to cancer therapies, however,
would not be straightforward. First, a tumor mass is unlike the
homogeneous cancer cells of a cell line. Due to tumor hetero-
geneity, some cells in a tumor may express IGF1R, whereas
other cells may express EGFR, and yet other cells may express
insulin receptors, and all these cells may generate PI3K-AKT
pro-survival signals. If we were to use only an IGF1R receptor
inhibitor, the cancer cells expressing EGFR or insulin recep-
tors would not be eliminated, thus eventually causing tumor
recurrence. Thus, AKT or at least, PI3K, must be inhibited. If
we were to use LY294002, as we did in this article to treat
mice bearing tumors, some mice would die from the treatment
[29]. This result is because the PI3K-AKT pathway is activat-
ed in many healthy tissues, and most of its inhibitors have
unwanted side effects. For this reason, we used beta-
cyclodextrin (βCD) to interrupt the signaling between PI3K
and AKT. The compound, βCD, is a reversible inhibitor of
PI3K-AKT, and its effect in mice lasts only approximately 4 h
and causes limited side effects. To take advantage of the ab-
sence of AKT, we needed to induce apoptosis very quickly.
Therefore, we combined βCD with 2DG-ABT. The
2DG-βCD-ABT combination induced apoptosis in cultured
UOK121 cells and also induced tumor regression in mice
grafted with UOK121 cells. The results of the 2DG-βCD-
ABT combination therapy have been reported [10].
Finally, it may still be possible to find a mild tyrosine ki-
nase inhibitor that could attenuate AKT activity long enough
to reduce Mcl-1 protein levels [30]. In some cells, 24 h might
be enough to sufficiently reduceMcl-1 protein levels such that
ABT alone can induce apoptosis. In these scenarios, however,




Most of the experiments presented here were performed at
least twice. Furthermore, some of the experiments were repli-
cated in different cell lines but with different doses and time
points, which were determined for each cell line in prelimi-
nary experiments.
The anti-P-PI3K antibody was obtained from Santa Cruz,
the polyclonal anti-PI3K was from Pierce, the anti-HIF1a an-
tibody was from BD Transduction Laboratories, the cyto-
chrome c antibody was from BD Pharmingen (Cat. 556433
for blots), and the anti-β-tubulin antibody was from BD
Bioscience. For pY-IGF1R, we used the anti-pY1135/1136
Tumor Biol. (2016) 37:13295–13306 13303
IGF1R antibody from CST (Cat#3024), and for pS-AKT, we
used the anti-pSer 473 AKT1 antibody from Upstate (Cat#05-
736). All other primary antibodies were purchased from Cell
Signal (CST). Secondary antibodies conjugated with HRP
were purchased fromGEHealthcare. Most of these antibodies
have been tested for specificity by us and other groups. ABT-
263 was purchased from ChemieTek; 2-Deoxy-D-glucose
was purchased from Sigma. The pan-caspase inhibitor z-
VAD was purchased from Promega. Picropodophyllin was
purchased from COSMO Bioscience. PD98509, an ERK in-
hibitor, was purchased from Merck, and LY29402, a PI3K
inhibitor, was purchased from CST.
Cell lines and cell culture
Renal cell carcinoma cell lines stably transfected with an emp-
ty vector or an expression vector encodingVHLwere from the
Harada Laboratory (Kyoto University Hospital, Dept. of
Anesthesia, Japan), and UOK121 and UOK121 + VHL cells
stably transfected with the VHL expression vector were kind
gifts from Dr. Marston Linehan [9] (Center for Cancer
Research, Urologic Oncology Branch, NCI). These cells were
all cultured in high-glucose (4.5 g/L) DMEM supplemented
with 10 % FBS, unless stated otherwise. To restore epigenet-
ically silenced VHL expression in UOK121 cells, we cultured
the cells in medium containing 5.0 μM 5-Aza-dCyd
(Invitrogen) for 10 days [9]. The restoration of VHL expres-
sion and down regulation of IGF1R were verified by western
blotting.
Western blot and immunoprecipitation
We typically ran 20 μg of proteins per lane for the western
blots. We usually ran the same set of samples on multiple gels
so as to minimize the number of times we had to re-probe the
membrane. The concentration of acrylamide/bis in the gels
varied and was dependent on the size of proteins of interest.
For immunoprecipitation, 200 μg of protein was resuspended
in 20mMTris pH 7.5, 1% Triton-X 100, 150 mMNaCl, 10%
glycerol, and phosphatase inhibitor cocktail from Cell
Signaling (#58709S) and mixed with Protein G Sepharose or
Protein A Sepharose (Sigma P3296/P9242) pre-conjugated
with the antibodies for immunoprecipitation.
FACS analysis
After apoptosis was chemically induced, the cells were
washed in PBS, re-incubated in regular medium and incubated
overnight. A cell death assay was performed the next morning
using the Propidium Iodide Incorporation assay. Cells were
analyzed with BD Facs Canto II or FacsCalibur II, and the
results were analyzed by FlowJo. These experiments were
performed in triplicate for each condition, and the error bars
indicate the standard deviations. Thus, for each FACS run
presented in Sup Fig. 1, we analyzed over 50 samples, includ-
ing controls.
IGF1R and AKT depletion
IGF1R protein was depleted from renal cancer cells using
siRNA purchased from Cell Signaling (Cat 6610). The
siRNA was transfected into renal cancer cell lines using
Lipofectamine 2000 (Life Technologies), according to the
manufacturer’s protocol. IGF1R depletion was confirmed by
western blotting. AKT isoforms 1 & 2 were depleted from
RCC4 cells using siRNA (Cat. 6621) from Cell Signaling,







cc c c c c
c
c
Normally Bak is sequestered






























Fig. 6 The model of signaling
pathways in RTK-expressing
cells. (1) In RTK-activated cells,
AKT is activated by PI3K, stabi-
lizing the Bak-Mcl-1 association
in the mitochondria. (2) In the
absence of activated AKT, 2DG
can induce the dissociation of
Mcl-1 from Bak. (3) ABT-263
binds to Bcl-xL with high affinity,
dissociating it from Bak. (4)
When freed from all its inhibitory
associations, Bak is activated,
forming a pore on the mitochon-
dria. (5) Cytochrome c is released
into cytosol. (6) The release of
cytochrome c triggers the assem-
bly of the death inducing
apoptosome in the cytosol
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Live cell counts
Live cells were distinguished from dead cells by suspending
the cells in trypan blue in PBS and counting them with an
Invitrogen cell counter. These experiments were performed
in triplicate.
Statistical analyses
Statistical analysis was performed using GraphPad,
http://www.graphpad.com/quickcalcs/ttest1.cfm? Format=C.
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